-
Bose has achieved results in promoting drug reform, and the people's sense of gain has gradually increased
Time of Update: 2022-12-30
Since participating in the procurement of pharmaceutical groups, the city has completed the signing of drug contracts and procurement amounts of 650 million yuan, an average reduction of 56%, saving procurement costs of 828 million yuan, and reducing the economic burden of patients by 328 million yuan according to the reimbursement ratio of the medical insurance fund policy.
-
Sinovac Pharmaceutical joins hands with Tonghua Dongbao to add new products to overseas commercialization
Time of Update: 2022-12-30
The strength of overseas commercialization is highlightedIn recent years, with the strengthening of overseas high-quality biopharmaceutical market demand, Sinovac Pharmaceutical has actively established strategic cooperation with domestic and foreign biotechnology companies by relying on more than 20 years of accumulated commercialization experience, global three-dimensional marketing network and channel resources, and rapid overseas registration capabilities.
-
Pharmaceutical commercial stocks rebounded and will continue to maintain a rapid growth trend
Time of Update: 2022-12-30
82 billion yuan in the first three quarters of this year (+20%); Achieved net profit attributable to owners of RMB920 million (+12.
82 billion yuan in the first three quarters of this year (+20%); Achieved net profit attributable to owners of RMB920 million (+12.
-
Guangshengtang 20cm up limit, Chinese medicine 2 plates... On the 16th, the pharmaceutical sector became active again
Time of Update: 2022-12-30
【Pharmaceutical Network Pharmaceutical Stock Market】 On December 16, the intraday Chinese medicine sector was active again, Guangshengtang hit the 20cm price limit, China Pharmaceutical achieved 2 con
-
In 2029, the out-of-hospital market will reach 160 million yuan, but the "card slot" of pharmaceutical companies is not easy
Time of Update: 2022-12-30
In recent years, not only multinational pharmaceutical companies, including Guangzhou Medicine Baiyunshan, Harbin Pharmaceutical, Xi'an Janssen, Yiling, Buchang, Jiangsu Wanbang, Besunyen and other local pharmaceutical companies have successively cooperated with emerging industry platforms.
-
The pharmaceutical sector has changed! Lingkang Pharmaceutical, Yisheng Pharmaceutical, etc
Time of Update: 2022-12-30
On the news, Xinhua Pharmaceutical said on the interactive platform on December 21 that the company is actively cooperating with the relevant requirements of the national epidemic prevention policy, working overtime to produce urgently needed drugs in the market and making every effort to ensure market supply.
-
The domestic pharmaceutical equipment industry is growing against the trend, and its revenue may exceed 25 billion yuan in 2023
Time of Update: 2022-12-30
Data show that in recent years, the sales of the pharmaceutical equipment industry have shown a gradual improvement trend, and it is predicted that the sales of this market will reach 23.
-
Xu Haoyu: Life and health enterprises have the responsibility to establish a healthy and civilized concept
Time of Update: 2022-12-30
Boao, November 28, Xinhuanet (Wu Qilong) From November 25 to 28, the 2022 Boao Forum for Chinese Entrepreneurs was held in Boao, Hainan. Xu Haoyu, secretary of the party committee, chairman and gener
-
Establish a "white list" management system to promote pharmaceutical companies to expand production and increase the supply of key drug markets
Time of Update: 2022-12-30
Jiao Yahui, Director of the Department of Medical Affairs of the National Health Commission:In response to the shortage of drugs in some regions caused by the recent increase in the number of patients and the surge in drug demand, the relevant person in charge of the Ministry of Industry and Information Technology introduced that enterprises have been promoted to rapidly stabilize production, expand capacity and expand production, and increase the supply of key drug markets.
-
Investment and financing in the field of medicine and biology are active, and enterprise innovation will usher in accelerated development
Time of Update: 2022-12-30
Prior to this, Guosen Pharmaceutical also announced the completion of a series B+ financing of nearly 100 million yuan, after the completion of this round of financing, the company will continue to focus on and deepen the clinical research of innovative drugs in cutting-edge pipelines, deepen business and technology, and continue to highlight the advantages in the field of cell and gene therapy (CGT).
-
What are the symptoms of people who re-yang People who re-yang generally return to the yang within a few days
Time of Update: 2022-12-30
4. Eye symptoms:Patients with novel coronavirus pneumonia may experience eye discomfort, and common eye symptoms include itchy eyes, eye pain, conjunctival hyperemia, conjunctival edema, etc.
4. Eye symptoms:Patients with novel coronavirus pneumonia may experience eye discomfort, and common eye symptoms include itchy eyes, eye pain, conjunctival hyperemia, conjunctival edema, etc.
-
License-in "not fragrant"? Another IPO of the science and technology innovation board of pharmaceutical companies was pressed the "pause button"
Time of Update: 2022-12-30
【Pharmaceutical Network Market Analysis】In recent years, with the normalization of centralized procurement, medical insurance control fees and other policies, the domestic pharmaceutical industry has
-
The market space for biopharmaceutical disposable consumables and equipment is broad, and pharmaceutical companies will usher in benefits
Time of Update: 2022-12-30
In the future, with the commissioning of Chutian Siyote plant, the industry is expected to provide guarantee for the production capacity of Chutian Technology's disposable bioreactors, liquid preparation bags, storage bags and their membranes.
-
New infrastructure presses the "accelerator button", and the traditional pharmaceutical equipment industry will also "go to the cloud"
Time of Update: 2022-12-30
In addition, affected by the epidemic in recent years, more traditional enterprises, including pharmaceutical companies and pharmaceutical equipment enterprises, have actively transformed under the impact of production and operation, and sought more possibilities online by embracing digitalization, which further highlights the role of new infrastructure.
-
In 2023, the opportunities in the pharmaceutical sector look at two keywords
Time of Update: 2022-12-30
On the one hand, "anti-epidemic" related products and anti-cold drugs and their industrial chain are still expected to benefit, including anti-cold drugs (including traditional Chinese medicine) with high performance certainty, retail pharmacies, household equipment such as oxygen generators, antigen testing, etc.
-
Many pharmaceutical companies said that they will increase production capacity, will the demand for upstream equipment usher in growth?
Time of Update: 2022-12-30
【Pharmaceutical Network Market Analysis】Recently, under the prospect of ibuprofen and other antipyretic and analgesic drugs setting off a rush to buy or even some products in short supply, the production capacity of related pharmaceutical companies has also attracted market attention.
-
This pharmaceutical stock was surveyed by more than 100 institutions in 2 days!
Time of Update: 2022-12-30
In recent years, thanks to the significant increase in sales of protective products in medical consumables, the company's performance has also ushered in explosive growth.
In recent years, thanks to the significant increase in sales of protective products in medical consumables, the company's performance has also ushered in explosive growth.
-
The pharmaceutical sector has changed! Guizhou Sanli, Saili Medical and many other stocks rose to the limit
Time of Update: 2022-12-30
According to the analysis, the reasons for the change in the stock include: the company is a traditional Chinese medicine enterprise, with products such as Huo Xiang Zhengqi Capsules, Angong Niuhuang Pills, and Suhe Xiang Pills, and has launched new drug research and registration projects for 6 classic Chinese medicine series.
-
Ascletis Pharmaceutical, Clover and other B-class pharmaceutical stocks strengthened
Time of Update: 2022-12-30
According to the data, Clover is a biotechnology company in the clinical trial stage, committed to developing novel vaccine and biotherapeutic product candidates for infectious diseases, cancer and autoimmune diseases.
-
The pharmaceutical sector continues to diverge! Northeast Pharmaceutical 6 days 4 boards, Shu Taishen and other bucked the trend
Time of Update: 2022-12-30
Northeast Pharmaceutical, which recently attracted attention due to "2 yuan and 20 tablets of antipyretic drugs", rose again after the opening on December 20, achieving "6 days and 4 boards", as of the close of the day, the stock rose 10.
